Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression:: the protection varies with duration of infection

被引:83
作者
Mulherin, SA
O'Brien, TR
Ioannidis, JPA
Goedert, JJ
Buchbinder, SP
Coutinho, RA
Jamieson, BD
Meyer, L
Michael, NL
Pantaleo, G
Rizzardi, GP
Schuitemaker, H
Sheppard, HW
Theodorou, ID
Vlahov, D
Rosenberg, PS
机构
[1] NCI, Biostat Branch, Div Canc Epidemiol & Genet, DHHS,NIH, Rockville, MD 20852 USA
[2] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA
[3] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece
[4] Ioannina Biomed Res Inst, GR-45110 Ioannina, Greece
[5] San Francisco Dept Publ Hlth, HIV Res Stn, San Francisco, CA 94102 USA
[6] Municipal Hlth Serv Amsterdam, Dept Publ Hlth & Environm, Amsterdam, Netherlands
[7] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA
[8] Hop Bicetre, INSERM, U292, Serv Epidemiol, F-94276 Le Kremlin Bicetre, France
[9] Walter Reed Army Med Ctr, Div Retrovirol, Rockville, MD 20850 USA
[10] CHU Vaudois, Lab AIDS Immunopathogenesis, CH-1011 Lausanne, Switzerland
[11] Univ Amsterdam, Acad Med Ctr, Sanquin Res CLB & Lanssteiner Lab, Dept Clin Viroimmunol, NL-1105 AZ Amsterdam, Netherlands
[12] Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Berkeley, CA 94704 USA
[13] Hop La Pitie Salpetriere, Lab Cent Immunol Cellulaire & Tissulaire, F-75013 Paris, France
[14] CNRS, UMR 7627, F-75013 Paris, France
[15] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY 10029 USA
关键词
AIDS; alleles; CCR5; CCR2; chemokine receptors; HIV-1;
D O I
10.1097/00002030-200302140-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To examine temporal variation in the effects of CCR5-Delta32 and CCR2-641 chemokine receptor gene polymorphisms on HIV-1 disease progression. Design: Pooled analysis of individual patient data from 10 cohorts of HIV-1 seroconverters from the United States, Europe, and Australia. Methods: We studied HIV-1 seroconverters of European (n = 1635) or African (n = 215) ancestry who had been genotyped for CCR5-A32 and CCR2-641. We used Cox proportional hazards models with time-varying coefficients to determine whether the genetic protection against AIDS (1987 case definition) and death varied with time since seroconversion. Results: Protection against AIDS conferred by CCR5-A32 held constant at a 31% (RH 0.69, 95% Cl 0.54, 0.88) reduction in risk over the course of HIV-1 infection, whereas protection against death held constant at a 39% reduction in risk (RH 0.61, 95% Cl 0.45, 0.88). When the period from AIDS to death was isolated, the survival benefit of CCR5-A32 diminished 2 years after AIDS. Protection against AIDS conferred by CCR2-641 was greatest early in the disease course. Compared with individuals without CCR5-Delta32 or CCR2-641, individuals with one or two copies of CCR2-641 had a 58% lower risk of AIDS during the first 4 years after seroconversion (RH 0.42, 95% CI 0.23,0.76), a 19% lower risk during the subsequent 4 years (RH 0.81, 95% Cl 0.59, 1.12), and no significant protection thereafter. Conclusion: The protection against AIDS provided by CCR5-Delta32 is continuous during the course of infection. In contrast, the protection provided by CCR2-641 is greatest early in the course of infection. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:377 / 387
页数:11
相关论文
共 38 条
[1]  
Akaike H., 1973, 2 INT S INFORM THEOR, P267, DOI [DOI 10.1007/978-1-4612-1694-0_15, 10.1007/978-1-4612-1694-0_15]
[2]  
BENKIRANE M, 1998, AM J HUM GENET, V62, P1507
[3]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[4]   Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J].
Dean, M ;
Carrington, M ;
Winkler, C ;
Huttley, GA ;
Smith, MW ;
Allikmets, R ;
Goedert, JJ ;
Buchbinder, SP ;
Vittinghoff, E ;
Gomperts, E ;
Donfield, S ;
Vlahov, D ;
Kaslow, R ;
Saah, A ;
Rinaldo, C ;
Detels, R ;
OBrien, SJ .
SCIENCE, 1996, 273 (5283) :1856-1862
[5]   Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals [J].
Eugen-Olsen, J ;
Iversen, AKN ;
Benfield, TL ;
Koppelhus, U ;
Garred, P .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 (02) :110-116
[6]   Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals [J].
EugenOlsen, J ;
Iversen, AKN ;
Garred, P ;
Koppelhus, U ;
Pedersen, C ;
Benfield, TL ;
Sorensen, AM ;
Katzenstein, T ;
Dickmeiss, E ;
Gerstoft, J ;
Skinhoj, P ;
Svejgaard, A ;
Nielsen, JO ;
Hofmann, B .
AIDS, 1997, 11 (03) :305-310
[7]   Dual effect of CCR5 Delta 32 gene deletion in HIV-1-infected patients [J].
Garred, P ;
EugenOlsen, J ;
Iversen, AKN ;
Benfield, TL ;
Svejgaard, A ;
Hofmann, B ;
Koppelhus, U ;
Pedersen, C ;
Sorensen, AM ;
Katzenstein, T ;
Gerstoft, J ;
Skinhoj, P ;
Nielsen, JO ;
Dickmeiss, E .
LANCET, 1997, 349 (9069) :1884-1884
[8]   Distinctive effects of CCR5, CCR2, and SSDF1 genetic polymorphisms in AIDS progression [J].
Hendel, H ;
Hénon, N ;
Lebuanec, H ;
Lachgar, A ;
Poncelet, H ;
Caillat-Zucman, S ;
Winkler, CA ;
Smith, MW ;
Kenefic, L ;
O'Brien, S ;
Lu, W ;
Andrieu, JM ;
Zagury, D ;
Schächter, F ;
Rappaport, J ;
Zagury, JF .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 19 (04) :381-386
[9]   Association between CCR5 genotype and the clinical course of HIV-1 infection [J].
Husman, AMD ;
Koot, M ;
Cornelissen, M ;
Keet, IPM ;
Brouwer, M ;
Broersen, SM ;
Bakker, M ;
Roos, MTL ;
Prins, M ;
deWolf, F ;
Coutinho, RA ;
Miedema, F ;
Goudsmit, J ;
Schuitemaker, H .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :882-+
[10]   Effects of CCR5-Δ32, CCR2-641, and SDF-1 3′A alleles on HIV-1 disease progression:: An international meta-analysis of individual-patient data [J].
Ioannidis, JPA ;
Rosenberg, PS ;
Goedert, JJ ;
Ashton, LJ ;
Benfield, TL ;
Buchbinder, SP ;
Coutinho, RA ;
Eugen-Olsen, J ;
Gallart, T ;
Katzenstein, TL ;
Kostrikis, LG ;
Kuipers, H ;
Louie, LG ;
Mallal, SA ;
Margolick, JB ;
Martinez, OP ;
Meyer, L ;
Michael, NL ;
Operskalski, E ;
Pantaleo, G ;
Rizzardi, GP ;
Schuitemaker, H ;
Sheppard, HW ;
Stewart, GJ ;
Theodorou, ID ;
Ullum, H ;
Vicenzi, E ;
Vlahov, D ;
Wilkinson, D ;
Workman, C ;
Zagury, JF ;
O'Brien, TR .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (09) :782-795